Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 GBX | 0.00% | -5.88% | -5.88% |
Apr. 25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
Apr. 23 | N4 Pharma loss widens but "great optimism" remains | AN |
Business Summary
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 13-12-31 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 46 | 20-07-13 | |
Founder | 59 | 13-12-31 | |
Chris Britten
CHM | Chairman | - | 19-05-19 |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 268,780,349 | 208,900,995 ( 77.72 %) | 0 | 77.72 % |
Company contact information
N4 Pharma Plc
Weston House Bradgate Park View
DE73 5UJ, Chellaston
+44 1332 690061
http://www.n4pharma.comSector
1st Jan change | Capi. | |
---|---|---|
-5.88% | 2.69M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- ONZ Stock
- Company N4 Pharma Plc